WO2011145343A1 - 5-アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬 - Google Patents
5-アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬 Download PDFInfo
- Publication number
- WO2011145343A1 WO2011145343A1 PCT/JP2011/002770 JP2011002770W WO2011145343A1 WO 2011145343 A1 WO2011145343 A1 WO 2011145343A1 JP 2011002770 W JP2011002770 W JP 2011002770W WO 2011145343 A1 WO2011145343 A1 WO 2011145343A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- malaria
- ala
- therapeutic agent
- compound
- derivative
- Prior art date
Links
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 229960002749 aminolevulinic acid Drugs 0.000 title claims abstract description 53
- 239000003430 antimalarial agent Substances 0.000 title claims abstract description 31
- 239000004480 active ingredient Substances 0.000 title claims abstract description 13
- 201000004792 malaria Diseases 0.000 claims abstract description 65
- 239000003814 drug Substances 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 15
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 52
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 24
- 229910052751 metal Inorganic materials 0.000 claims description 21
- 239000002184 metal Substances 0.000 claims description 21
- 229910052742 iron Inorganic materials 0.000 claims description 12
- 230000003449 preventive effect Effects 0.000 claims description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 238000011282 treatment Methods 0.000 abstract description 16
- 244000045947 parasite Species 0.000 abstract description 12
- 208000035473 Communicable disease Diseases 0.000 abstract description 5
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 32
- 230000000694 effects Effects 0.000 description 22
- -1 cyclododecyl Chemical group 0.000 description 17
- 229940079593 drug Drugs 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000007796 conventional method Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 150000003278 haem Chemical class 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 7
- 229960003677 chloroquine Drugs 0.000 description 7
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 7
- 238000002428 photodynamic therapy Methods 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 6
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 6
- 125000004494 ethyl ester group Chemical group 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229940091250 magnesium supplement Drugs 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 241000024188 Andala Species 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 238000002738 Giemsa staining Methods 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QSHWIQZFGQKFMA-UHFFFAOYSA-N porphobilinogen Chemical compound NCC=1NC=C(CCC(O)=O)C=1CC(O)=O QSHWIQZFGQKFMA-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 4
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 description 4
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 3
- 235000001258 Cinchona calisaya Nutrition 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 229950003776 protoporphyrin Drugs 0.000 description 3
- 229960000948 quinine Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229960001962 mefloquine Drugs 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
- 229960000611 pyrimethamine Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229960004673 sulfadoxine Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 2
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical class CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- LPOSZYSKJWFIQH-UHFFFAOYSA-N 2-aminoacetic acid;iron Chemical compound [Fe].NCC(O)=O LPOSZYSKJWFIQH-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZCFFYALKHPIRKJ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(=C(C)C(=CC=3C(C)=C(CCC(O)=O)C(N=3)=C3)N2)C=C)=C(C)C(C=C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 ZCFFYALKHPIRKJ-UHFFFAOYSA-N 0.000 description 1
- MOTVYDVWODTRDF-UHFFFAOYSA-N 3-[7,12,17-tris(2-carboxyethyl)-3,8,13,18-tetrakis(carboxymethyl)-21,22-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CC(O)=O)C(=CC=3C(=C(CC(O)=O)C(=C4)N=3)CCC(O)=O)N2)CCC(O)=O)=C(CC(O)=O)C(CCC(O)=O)=C1C=C1C(CC(O)=O)=C(CCC(=O)O)C4=N1 MOTVYDVWODTRDF-UHFFFAOYSA-N 0.000 description 1
- ZLHFONARZHCSET-UHFFFAOYSA-N 5-aminolevulinic acid hydrochloride Chemical compound Cl.NCC(=O)CCC(O)=O ZLHFONARZHCSET-UHFFFAOYSA-N 0.000 description 1
- GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- HNBPGMZUKDCQEE-UWTATZPHSA-N D-alanyl phosphate Chemical compound C[C@@H](N)C(=O)OP(O)(O)=O HNBPGMZUKDCQEE-UWTATZPHSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000005569 Iron sulphate Substances 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241001505483 Plasmodium falciparum 3D7 Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- DYPHJEMAXTWPFB-UHFFFAOYSA-N [K].[Fe] Chemical compound [K].[Fe] DYPHJEMAXTWPFB-UHFFFAOYSA-N 0.000 description 1
- MVXPPHMUGOVFBT-UHFFFAOYSA-L [NH4+].C(C)(=O)[O-].C(C)(=O)O.C(C)(=O)O.C(C)(=O)[O-].C(C)(=O)[O-].[Mg+2].NCCNCCN Chemical compound [NH4+].C(C)(=O)[O-].C(C)(=O)O.C(C)(=O)O.C(C)(=O)[O-].C(C)(=O)[O-].[Mg+2].NCCNCCN MVXPPHMUGOVFBT-UHFFFAOYSA-L 0.000 description 1
- VAGGJWZQGWBRPQ-QTNFYWBSSA-K [Na+].[Fe+2].C(=O)([O-])C(C(=O)[O-])N[C@@H](CCC(=O)O)C(=O)[O-] Chemical compound [Na+].[Fe+2].C(=O)([O-])C(C(=O)[O-])N[C@@H](CCC(=O)O)C(=O)[O-] VAGGJWZQGWBRPQ-QTNFYWBSSA-K 0.000 description 1
- JVOGSHDZLOJKKR-MXFMKSRJSA-I [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O Chemical compound [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O JVOGSHDZLOJKKR-MXFMKSRJSA-I 0.000 description 1
- XKPMDXAYDXOODD-UHFFFAOYSA-N [Na].[Na].[Mg].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O Chemical compound [Na].[Na].[Mg].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O XKPMDXAYDXOODD-UHFFFAOYSA-N 0.000 description 1
- XUKAFOLYJQTZHL-UHFFFAOYSA-N [Na].[Na].[Zn].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O Chemical compound [Na].[Na].[Zn].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O XUKAFOLYJQTZHL-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 229960004991 artesunate Drugs 0.000 description 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- PLKYGPRDCKGEJH-UHFFFAOYSA-N azane;2-hydroxypropane-1,2,3-tricarboxylic acid;iron Chemical compound N.[Fe].OC(=O)CC(O)(C(O)=O)CC(O)=O PLKYGPRDCKGEJH-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- FJZZHNSAKKNYJJ-QTNFYWBSSA-N diazanium;(2s)-2-(dicarboxymethylamino)pentanedioate Chemical compound [NH4+].[NH4+].OC(=O)C(C(O)=O)N[C@H](C([O-])=O)CCC([O-])=O FJZZHNSAKKNYJJ-QTNFYWBSSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000011706 ferric diphosphate Substances 0.000 description 1
- 235000007144 ferric diphosphate Nutrition 0.000 description 1
- VEPSWGHMGZQCIN-UHFFFAOYSA-H ferric oxalate Chemical compound [Fe+3].[Fe+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O VEPSWGHMGZQCIN-UHFFFAOYSA-H 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960001604 ferrous succinate Drugs 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 108010080417 hemozoin Proteins 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- ATEAWHILRRXHPW-UHFFFAOYSA-J iron(2+);phosphonato phosphate Chemical compound [Fe+2].[Fe+2].[O-]P([O-])(=O)OP([O-])([O-])=O ATEAWHILRRXHPW-UHFFFAOYSA-J 0.000 description 1
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- APVZWAOKZPNDNR-UHFFFAOYSA-L iron(ii) citrate Chemical compound [Fe+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O APVZWAOKZPNDNR-UHFFFAOYSA-L 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- PJJZFXPJNUVBMR-UHFFFAOYSA-L magnesium benzoate Chemical compound [Mg+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 PJJZFXPJNUVBMR-UHFFFAOYSA-L 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LQPLDXQVILYOOL-UHFFFAOYSA-I pentasodium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O LQPLDXQVILYOOL-UHFFFAOYSA-I 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- 229960005385 proguanil Drugs 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WRNAXXCYSNLIJM-UHFFFAOYSA-K sodium 2-hydroxypropane-1,2,3-tricarboxylate 2-hydroxypropane-1,2,3-tricarboxylic acid iron(2+) Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].C(CC(O)(C(=O)O)CC(=O)O)(=O)O.[Fe+2] WRNAXXCYSNLIJM-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- KXFFQVUPQCREHA-UHFFFAOYSA-K sodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KXFFQVUPQCREHA-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- YUMLNTJCWGYGQU-UHFFFAOYSA-N zinc azane Chemical compound N.N.[Zn+2] YUMLNTJCWGYGQU-UHFFFAOYSA-N 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- FUTVBRXUIKZACV-UHFFFAOYSA-J zinc;3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate Chemical compound [Zn+2].[N-]1C2=C(C)C(CCC([O-])=O)=C1C=C([N-]1)C(CCC([O-])=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 FUTVBRXUIKZACV-UHFFFAOYSA-J 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to an antimalarial drug useful for the prevention and treatment of infectious diseases caused by malaria parasites, and more particularly to a preventive and a therapeutic agent for malaria containing 5-aminolevulinic acid (ALA) or a derivative thereof as an active ingredient. .
- ALA 5-aminolevulinic acid
- Malaria is an infectious disease caused by malaria parasites transmitted by mottled mosquitoes, and has been the most feared infectious disease of civilization since history, mainly in the tropical and subtropical regions. Due to specific drugs such as quinine and chloroquine, the number of infected people decreased for a while, but drug-resistant protozoa began to be discovered in the late 1950s, and 300 to 500 million people are infected as revitalizing infections annually. The death toll is said to be 1 million or 2 million. Many other infectious diseases have been treated and prevented with vaccines.For example, smallpox has been completely eradicated, but in the case of malaria, infection is caused by protozoa and has a complicated life cycle. Despite research being conducted, even the clue of vaccine development has not been found, and it is said that vaccine development is inherently difficult.
- PDT treatment is a treatment method that combines a photosensitizer and light irradiation.
- ALA itself does not have photosensitization, it is metabolized in the body to become the photosensitizer protoporphyrin IX (PPIX), and is therefore used for PDT treatment of cancer (see, for example, Patent Documents 1 to 3).
- PDT therapy using ALA examination using the malaria parasite is performed on the petri dish (for example, refer nonpatent literature 1).
- PDT treatment certainly showed an effect on malaria, but in order to show a slight effect on normal room light illumination, it was necessary to add as much as 2 mM ALA to the medium, which is at least 20 g for a person weighing 60 kg. It is necessary to administer ALA / hydrochloride of ALA, and administration is impossible due to toxicity problems. In order to see a sufficient protocidal effect when 0.2 mM equivalent to 2 g, which is equivalent to twice the dose that can normally be tolerated by humans, is administered to the medium, light irradiation for 30 minutes with a powerful 410 W projector lamp was necessary. These are tests using a transparent medium on a petri dish and have high light transmission, but in fact, malaria parasites parasitize blood erythrocytes, so light irradiation is impractical, and further studies are ongoing. Not.
- Patent Document 4 a hair growth agent (for example, see Patent Document 4) containing ALA and an iron compound as active ingredients and a rough skin preventing / ameliorating agent (for example, see Patent Document 5) have been proposed.
- An object of the present invention is to provide an antimalarial drug useful for the prevention and treatment of malaria containing 5-aminolevulinic acid (ALA) or a derivative thereof as an active ingredient.
- ALA 5-aminolevulinic acid
- the present inventors closely tracked the life cycle of malaria parasites, the mechanism of action of antimalarial drugs represented by quinine and chloroquine, and studies on resistance to these malaria drugs.
- the malaria parasite has the ability to polymerize heme, detoxifies hem into hemozoin, and existing antimalarial drugs It has been found that the main mechanism of action is to inhibit the polymerization of this heme, and that the mechanism of drug resistance is due to the promotion or detoxification of drug excretion.
- malaria has a complex life cycle and overcomes immunity, but it has the greatest weakness that it is injured by heme because it must be in close proximity to heme to feed on hemoglobin. It is.
- ALA or a derivative thereof which is in the rate-limiting step of heme synthesis, may have an antimalarial action directly or through its metabolic intermediate. That is, ALA or a derivative thereof known as a compound having an anemia improving effect is converted directly or into heme, or its intermediates porphobilinogen (PBG), uroporphyrin, coproporphyrin, proto It was thought that intermediate metabolites such as porphyrins may act to suppress the activity of malaria parasites in such a way as to directly or indirectly damage the protozoa or prevent the excretion of existing drugs.
- PBG porphobilinogen
- uroporphyrin uroporphyrin
- coproporphyrin proto It was thought that intermediate metabolites such as porphyrins may act to suppress the activity of malaria parasites in such a way as to directly or indirectly damage the protozoa or prevent the excretion of existing drugs.
- the inventors of the present invention have further studied various methods regarding administration methods, combinations with drugs that have already acquired tolerance, dosages, etc., and have established a treatment or prevention agent for malaria containing ALA as an active ingredient. Finally, the present invention has been completed.
- the present invention (1) a preventive and / or therapeutic agent for malaria containing 5-aminolevulinic acid (ALA) or a derivative thereof or a pharmacologically acceptable salt thereof as an active ingredient, (2) ALA or a derivative thereof is represented by the following formula (I)
- R 1 represents a hydrogen atom or an acyl group
- R 2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aralkyl group, or an aryl group
- a prophylactic and / or therapeutic agent for malaria according to the above (1) which is a compound represented by: (3)
- the present invention relates to a preventive and / or therapeutic agent for malaria according to the above (2), wherein R 1 and R 2 are hydrogen atoms.
- the present invention also provides: (4) A prophylactic and / or therapeutic agent for malaria according to any one of (1) to (3) above, wherein one or more metal-containing compounds are used in combination, (5) The preventive and / or therapeutic agent for malaria according to (4) above, wherein the metal portion of the metal-containing compound is iron, magnesium or zinc.
- the present invention also provides: (6) The preventive and / or therapeutic agent for malaria according to any one of (1) to (5) above, wherein one or more existing antimalarial drugs are used in combination. , (7) The present invention relates to the preventive and / or therapeutic agent for malaria according to any one of (1) to (6) above, wherein the agent is used for administration to an antimalarial drug resistant patient.
- the present invention provides ALA or a derivative thereof or a pharmacologically acceptable salt thereof according to any one of (1) to (7) above used for the prevention and / or treatment of malaria, Use of ALA or a derivative thereof or a pharmaceutically acceptable salt thereof according to any one of (1) to (7) above for preventing and / or treating malaria, Use of ALA or a derivative thereof or a pharmacologically acceptable salt thereof according to any one of (1) to (7) in the manufacture of a medicament for preventing and / or treating malaria, A method for preventing and / or treating malaria with a pharmaceutical composition comprising as an active ingredient the ALA or derivative thereof according to any one of (1) to (7) or a pharmacologically acceptable salt thereof, The present invention relates to a method for preventing and / or treating malaria by administering a therapeutically effective amount of ALA or a derivative thereof or a pharmacologically acceptable salt thereof according to any one of (1) to (7).
- the antimalarial drug comprising the ALA of the present invention as an active ingredient has an excellent malaria treatment / prevention effect. Furthermore, when used in combination with existing antimalarial drugs, it has the effect of increasing drug efficacy or reducing the dose of existing malaria drugs with strong side effects.
- the antimalarial drug of the present invention is completely different in mechanism from existing antimalarial drugs and is considered to be resistant to drug resistance because it focuses on heme metabolism. Moreover, tolerance can be overcome by combining with existing drugs that have become resistant, and the effects of existing cheap and popular antimalarial drugs can be enhanced.
- the alkyl group is, for example, linear or branched Examples thereof include alkyl having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl and the like.
- the cycloalkyl group is a cycloalkyl having 3 to 8 carbon atoms in which a saturated or partially unsaturated bond may exist, specifically, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclododecyl, 1-cyclohexenyl and the like can be mentioned.
- the aralkyl group has the same aryl moiety as the following aryl group, and the alkyl part has the same meaning as the above alkyl group.
- aralkyl having 7 to 15 carbon atoms specifically, benzyl, phenethyl, phenylpropyl, phenylbutyl.
- aryl group examples include aryl having 6 to 14 carbon atoms, specifically, phenyl, naphthyl, anthryl, phenanthryl and the like.
- the acyl group is a linear or branched alkanoyl group having 1 to 8 carbon atoms, specifically formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl, benzylcarbonyl, etc., or carbon
- Examples of the aroyl group of formulas 7 to 14 include benzoyl, 1-naphthoyl, 2-naphthoyl and the like.
- examples of the ALA derivative include compounds in which the amino group of ALA is acylated and / or the carboxyl group is esterified.
- a compound in which the acyl group is formyl, acetyl, propionyl, butyryl and the like, and a compound in which the ester group is methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, etc. are preferable.
- Examples include methyl ester, acetyl and methyl ester, propionyl and methyl ester, butyryl and methyl ester, formyl and ethyl ester group, acetyl and ethyl ester, propionyl and ethyl ester, butyryl and ethyl ester.
- Pharmacologically acceptable salts of compound (I) include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts and the like.
- acid addition salts include hydrochloride, hydrobromide, hydroiodide, phosphate, nitrate, sulfate, and other inorganic acid salts, formate, acetate, propionate, toluenesulfonic acid Salt, succinate, oxalate, lactate, tartrate, glycolate, methanesulfonate, butyrate, valerate, citrate, fumarate, maleate, malate, etc.
- organic acid addition salts include organic acid addition salts.
- Examples of the metal salt include alkali metal salts such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium and calcium salt, and metal salts such as aluminum and zinc.
- Examples of ammonium salts include ammonium salts and alkylammonium salts such as tetramethylammonium salts.
- Examples of the organic amine salt include salts such as triethylamine salt, piperidine salt, morpholine salt, and toluidine salt.
- Compound (I) can be produced by any method of chemical synthesis, microorganism production, and enzyme production.
- an acyl group in an amino group in an ALA derivative, an ester group in a carboxyl group, or the like can be produced by acylation of an amino group, esterification of a carboxyl group, or the like by a conventional chemical synthesis method.
- compound (I) when it is desired to obtain a salt of compound (I), if compound (I) is obtained in the form of a salt, it can be purified as it is, and if it is obtained in a free form, it can be dissolved in an appropriate organic solvent. Alternatively, it may be suspended and an acid or base is added to form a salt by a conventional method.
- Compound (I) and pharmacologically acceptable salts thereof may exist in the form of adducts with water or various solvents, and these adducts can also be used as the antimalarial drug of the present invention. .
- the compound (I) that can be used as the antimalarial drug of the present invention is not particularly limited as long as it is the compound (I), but any one of the compounds (I) may be used alone or in appropriate combination of two or more. I can do it.
- Desirable compounds (I) include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester and pentyl ester, and hydrochlorides, phosphates and sulfates thereof. ALA hydrochloride and ALA phosphate are exemplified as the most desirable compounds.
- a metal-containing compound can also be used in combination with the compound (I).
- the metal-containing compound can be used as long as it does not cause hyperplasia. For example, it is 0.1 to 10 (w / w) times the amount of compound (I), preferably 0.5 to 5 ( w / w) times the amount, more preferably 0.8 to 2 (w / w) times the amount used in combination.
- metal portion of the metal-containing compound iron, magnesium, zinc, nickel, vanadium, cobalt and the like are preferable, and among them, porphyrin, iron involved in heme biosynthesis, magnesium, zinc are preferable, and these metal-containing compounds are There is no particular limitation as long as it is a compound containing the metal in the molecule and does not adversely affect the effects of the present invention.
- compounds containing iron in the molecule include ferrous citrate, sodium iron citrate, ammonium iron citrate, ferric pyrophosphate, heme iron, dextran iron, iron lactate, ferrous gluconate, Sodium diethylenetriaminepentaacetate, ammonium diethylenetriaminepentaacetate, sodium ethylenediaminetetraacetate, ammonium ethylenediaminepentaacetate, triethylenetetraamineiron, sodium iron dicarboxymethylglutamate, ammonium ammonium dicarboxymethylglutamate, iron lactoferrin, iron transferrin , Ferric chloride, iron sesquioxide, iron chlorophyllin sodium, ferritin iron, ferrous fumarate, ferrous pyrophosphate, sugar-containing iron oxide, iron acetate, iron oxalate, ferrous succinate, citric succinate Acid iron Potassium, iron sulphate, may be mentioned sulfide glycine iron.
- ferrous and sodium iron may be mentioned
- Compounds containing magnesium in the molecule include magnesium citrate, magnesium benzoate, magnesium acetate, magnesium oxide, magnesium chloride, magnesium hydroxide, magnesium carbonate, magnesium sulfate, magnesium silicate, magnesium nitrate, diethylenetriamine magnesium pentaacetate Ammonium, ethylenediaminetetraacetic acid magnesium disodium, and magnesium protoporphyrin are preferred.
- zinc chloride As a compound containing zinc in the molecule, zinc chloride, zinc oxide, zinc nitrate, zinc carbonate, zinc sulfate, diethylenetriaminepentaacetic acid zinc diammonium, ethylenediaminetetraacetic acid zinc disodium, zinc protoporphyrin, and zinc-containing yeast are preferable.
- metal-containing compounds may be used alone or in combination of two or more, and can be administered simultaneously with or separately from compound (I).
- the dosage form and administration method may be the same as those of Compound (I), or may be different.
- an existing antimalarial drug can also be used in combination with the compound (I).
- the existing antimalarial drug used in combination with compound (I) is not particularly limited, and examples thereof include quinine, chloroquine, mefloquine, sulfadoxine, pyrimethamine, atobacon, proguanil, artemethar, lumefantrin, artesunate, and primaquine. , Artesimine and the like.
- chloroquine, mefloquine, sulfadoxine, pyrimethamine, etc. are antimalarial drugs that have been used for a long time and are inexpensive.
- antimalarials may be used alone or in combination of two or more, and can be administered simultaneously or separately with Compound (I).
- the dosage form and administration method may be the same as those of Compound (I), or may be different.
- the present invention is administered to compound (I) alone or in combination with an existing antimalarial drug to a malaria patient, particularly a patient who has acquired resistance to an existing antimalarial drug. Can be used.
- Compound (I) or a pharmacologically acceptable salt thereof can be administered alone as it is, but other components such as other medicinal ingredients and nutrients can be added as necessary.
- Carriers that can be incorporated into compound (I) or a pharmaceutically acceptable salt thereof include organic or inorganic solid or liquid suitable for ingestion, usually inert pharmaceutically acceptable carrier materials Is used. Specific examples include carriers such as crystalline cellulose, gelatin, lactose, starch, magnesium stearate, talc, vegetable or animal fat and oil, gum, polyalkylene glycol and the like.
- Examples of the administration route include oral administration including sublingual administration, inhalation administration, intravenous administration including infusion, transdermal administration using a foaming agent, and parenteral administration such as suppositories.
- the dosage form may be a preparation such as an injection, instillation, tablet, capsule, fine granule, syrup, foaming agent, suppository and the like.
- These preparations can be produced according to a conventional method using a solvent, a dispersant, a bulking agent, an excipient and the like as appropriate.
- an injection may be produced according to a conventional method by adding water, physiological saline, vegetable oil, solubilizer, preservative and the like, and tablets may be produced by, for example, lactose, starch, magnesium stearate, hydroxypropyl cellulose, polyvinyl
- Various additives such as alcohol, surfactant, glycerin and the like may be mixed and manufactured according to a conventional method, and an inhalant may be manufactured according to a conventional method by adding, for example, lactose.
- the effective amount and frequency of administration of Compound (I) or a pharmacologically acceptable salt thereof vary depending on the dosage form, patient age, body weight, symptoms, etc., but the amount of Compound (I) contained in the preparation is:
- the total amount of compound (I) in terms of moles is usually 1 mg to 3000 mg, preferably 3 mg to 1000 mg, more preferably 10 mg to 700 mg per adult, in terms of ALA / hydrochloride.
- the administration time is not particularly selected in the morning or evening, but it is preferable to administer once a day or multiple times when the dose is large.
- the number of days of intake varies depending on the symptoms, but malaria is characterized by intermittent symptoms, so it is desirable to continue to take 3 to 4 days after symptom relief.
- a 24-year-old male suffering from malaria and who had a high fever was given a capsule containing 250 mg of ALA / hydrochloride prepared in Formulation Example 2.
- One hour after administration, headache, dizziness, nausea and malaise The fever decreased after 2 hours, and the symptoms disappeared completely after 1 day.
- the same capsule was administered once a day for 3 days, the symptoms did not recur, but the body temperature was about 0.5 degrees lower than the normal temperature.
- malaria parasites were identified but not increased. This revealed that ALA is effective in treating malaria.
- Example 1 A 32-year-old man who developed malaria took a prescribed amount of chloroquine. However, due to tolerance, he did not have a sufficient effect, and he felt headache, dizziness and nausea, and his fever increased and decreased at about 38 degrees. While taking chloroquine, the same capsule used in Example 1 was taken one day, and the symptoms improved in about half a day. After taking for 3 days, the intake was stopped, but the symptoms did not relapse. This is considered that ALA worked effectively for treatment by directly or against the resistance to chloroquine-resistant protozoa.
- aqueous iron (II) chloride solution was added to 1 ml of Plasmodium falciparumD3D7 culture solution with an infection rate of 0.3% to a final concentration of 0.1, 1, 10, 100 ⁇ M.
- sterilized water was added, three culture solutions of each concentration were prepared, and a 12-well plate was used. After culturing for 48 hours, the infection rate was measured by Giemsa staining.
- an ALA / hydrochloride aqueous solution was added to a final concentration of 200 ⁇ M, and an aqueous iron (II) chloride solution was added to a final concentration of 0.1, 1, 10, 100 ⁇ M.
- the infection rate was measured by Giemsa staining.
- Infection (growth) rate (%) [(Infection rate after 48 hours-infection rate at start of culture) / (control rate after 48 hours-infection rate at start of culture)] x 100 It was calculated from the following formula. The infection rate at the start of the culture was 0.3%.
- the rate of increase in infection rate due to culture was expressed as 100% where no iron and ALA were added. The results are shown in Table 1.
- Plasmodium falciparum 3D7 culture solution having an infection rate of 0.3% that was synchronously cultured on the ring stage by 5% sorbitol treatment was prepared, and the infection rate was measured in the same manner as in Example 5.
- Table 2 shows the results when the final concentration of ALA ⁇ hydrochloride is 200 ⁇ M.
- ALA is effective in suppressing malaria infection, and the effect is remarkably enhanced in combination with a metal-containing compound. Furthermore, in comparison with Example 5, it can be seen that the infection rate suppression effect by ALA and ALA and the metal-containing compound is particularly remarkable at the ring stage. If malaria can be suppressed at the ring stage, it is not possible to shift to the tropozoid phase, and if it is continuously cast, it can be removed from the infection, which is consistent with the observation results in Examples 1-4.
- iron (II) chloride at a final concentration of 10 ⁇ M
- ALA / hydrochloride at a final concentration of 200 ⁇ M
- a culture solution prepared in the same manner as in Example 7 was added with ALA / hydrochloride at a final concentration of 200 ⁇ M, cultured for 8 hours, and then irradiated with a white LED for 15 minutes. After further culturing for 8 hours and then measuring the infection rate by Giemsa staining, the infection rate was 1.8%. Even when the infection rate was high, ALA was shown to be effective in suppressing malaria infection.
- composition comprising 50.0 mg of ALA / phosphate, 57.36 mg of sodium ferrous citrate, 150 mg of pregelatinized starch, and 2.5 mg of silicon dioxide is prepared by a conventional method using No. 2 hard capsules.
- a composition comprising 25.0 mg of ALA / phosphate, 28.68 mg of ferrous sodium citrate, 204 mg of pregelatinized starch, and 2.5 mg of silicon dioxide is prepared by a conventional method using No. 2 hard capsules.
- the antimalarial drug containing the ALA of the present invention as an active ingredient can be used as a treatment / prevention agent for malaria. Furthermore, combining with existing antimalarial drugs can increase the efficacy or reduce the amount of existing malaria drugs with strong side effects.
- the antimalarial drug of the present invention can overcome the resistance when used in combination with an existing drug that has acquired resistance, and can enhance the effects of existing inexpensive and popular antimalarial drugs.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(1)5-アミノレブリン酸(ALA)若しくはその誘導体又はその薬理学的に許容される塩を有効成分として含有するマラリアの予防及び/又は治療剤や、
(2)ALA又はその誘導体が、下記式(I)
(3)R1及びR2が、水素原子であることを特徴とする上記(2)記載のマラリアの予防及び/又は治療剤に関する。
(4)一種又は二種以上の金属含有化合物を併用して使用することを特徴とする上記(1)~(3)のいずれか一項に記載のマラリアの予防及び/又は治療剤や、
(5)金属含有化合物の金属部分が、鉄、マグネシウム又は亜鉛であることを特徴とする上記(4)記載のマラリアの予防及び/又は治療剤に関する。
(6)一種又は二種以上の既存の抗マラリア薬を併用して使用することを特徴とする上記(1)~(5)のいずれか一項に記載のマラリアの予防及び/又は治療剤や、
(7)抗マラリア薬剤耐性患者に対して投与されるように用いられることを特徴とする上記(1)~(6)のいずれか一項に記載のマラリアの予防及び/又は治療剤に関する。
マラリアの予防及び/又は治療に使用する上記(1)~(7)のいずれか一項に記載のALA若しくはその誘導体又はその薬理学的に許容される塩や、
マラリアの予防及び/又は治療するための上記(1)~(7)のいずれか一項に記載のALA若しくはその誘導体又はその薬理学的に許容される塩の使用や、
マラリアの予防及び/又は治療するための医薬の製造における上記(1)~(7)のいずれか一項に記載のALA若しくはその誘導体又はその薬理学的に許容される塩の使用や、
(1)~(7)のいずれか一項に記載のALA若しくはその誘導体又はその薬理学的に許容される塩を有効成分として含有する医薬組成物によるマラリアの予防及び/又は治療方法や、
(1)~(7)のいずれか一項に記載のALA若しくはその誘導体又はその薬理学的に許容される塩の治療有効量を投与することによるマラリアの予防及び/又は治療方法に関する。
さらに、本発明は、化合物(I)単独あるいは既存の抗マラリア薬と併用して、マラリア患者、特に、既存の抗マラリア薬に対して耐性を獲得している患者に対して投与されるように用いることができる。
全員に、毎日一回、同カプセル一錠を投与し、5日目に再度血液を検査したところ、マラリア原虫は減少したものの存在は確認された。この間、発熱を含むマラリアの症状は再現しなかった。さらに2日間同カプセルを投与し、その後投与を中止したがマラリアの症状は現れなかった。完全に症状が消失したため治癒と見なし治癒後の血液検査は実施しなかった。
本例より、ALAがマラリア治療に有効であることが解る。
このことは、ALAがクロロキン耐性原虫にたいして直接にあるいは耐性を解除することで治療に有効に働いたものと考えられる。
[(48時間後の感染率-培養開始時の感染率)/(48時間後のコントロールの感染率-培養開始時の感染率)]×100
の式より算出した。なお、培養開始時の感染率は、0.3%にした。
ALA・リン酸塩50.0mg、クエン酸第一鉄ナトリウム57.36mg、α化デンプン150mg、二酸化ケイ素2.5mgからなる組成で、2号のハードカプセルを用いて、常法により調製する。
ALA・塩酸塩250mg含有ハードカプセルを、常法により調製する。
ALA・リン酸塩25.0mg、クエン酸第一鉄ナトリウム28.68mg、α化デンプン204mg、二酸化ケイ素2.5mgからなる組成で、2号のハードカプセルを用いて、常法により調製する。
Claims (7)
- 5-アミノレブリン酸(ALA)若しくはその誘導体又はその薬理学的に許容される塩を有効成分として含有するマラリアの予防及び/又は治療剤。
- R1及びR2が、水素原子であることを特徴とする請求項2記載のマラリアの予防及び/又は治療剤。
- 一種又は二種以上の金属含有化合物を併用して使用することを特徴とする請求項1~3のいずれか一項に記載のマラリアの予防及び/又は治療剤。
- 金属含有化合物の金属部分が、鉄、マグネシウム又は亜鉛であることを特徴とする請求項4記載のマラリアの予防及び/又は治療剤。
- 一種又は二種以上の既存の抗マラリア薬を併用して使用することを特徴とする請求項1~5のいずれか一項に記載のマラリアの予防及び/又は治療剤。
- 抗マラリア薬剤耐性患者に対して投与されるように用いられることを特徴とする請求項1~6のいずれか一項に記載のマラリアの予防及び/又は治療剤。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11783280.8A EP2572711B1 (en) | 2010-05-19 | 2011-05-18 | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient |
NZ603465A NZ603465A (en) | 2010-05-19 | 2011-05-18 | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient |
CN2011800242058A CN102905702A (zh) | 2010-05-19 | 2011-05-18 | 以5-氨基乙酰丙酸或其衍生物作为有效成分的抗疟药 |
KR1020127029697A KR20120137506A (ko) | 2010-05-19 | 2011-05-18 | 5-아미노레불린산 또는 그 유도체를 유효성분으로 하는 항말라리아약 |
US13/698,090 US9089530B2 (en) | 2010-05-19 | 2011-05-18 | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient |
BR112012029170A BR112012029170B1 (pt) | 2010-05-19 | 2011-05-18 | uso de um fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo |
AU2011256661A AU2011256661B2 (en) | 2010-05-19 | 2011-05-18 | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient |
JP2012515757A JP5582441B2 (ja) | 2010-05-19 | 2011-05-18 | 5−アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬 |
CA2799491A CA2799491C (en) | 2010-05-19 | 2011-05-18 | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient |
KR1020147026883A KR101723834B1 (ko) | 2010-05-19 | 2011-05-18 | 5-아미노레불린산 또는 그 유도체를 유효성분으로 하는 항말라리아약 |
US14/745,823 US9463175B2 (en) | 2010-05-19 | 2015-06-22 | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-115721 | 2010-05-19 | ||
JP2010115721 | 2010-05-19 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/698,090 A-371-Of-International US9089530B2 (en) | 2010-05-19 | 2011-05-18 | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient |
US14/745,823 Continuation US9463175B2 (en) | 2010-05-19 | 2015-06-22 | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011145343A1 true WO2011145343A1 (ja) | 2011-11-24 |
Family
ID=44991461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/002770 WO2011145343A1 (ja) | 2010-05-19 | 2011-05-18 | 5-アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬 |
Country Status (10)
Country | Link |
---|---|
US (2) | US9089530B2 (ja) |
EP (1) | EP2572711B1 (ja) |
JP (1) | JP5582441B2 (ja) |
KR (2) | KR20120137506A (ja) |
CN (2) | CN102905702A (ja) |
AU (1) | AU2011256661B2 (ja) |
BR (1) | BR112012029170B1 (ja) |
CA (1) | CA2799491C (ja) |
NZ (1) | NZ603465A (ja) |
WO (1) | WO2011145343A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014010206A1 (ja) * | 2012-07-13 | 2014-01-16 | Sbiファーマ株式会社 | 免疫寛容誘導剤 |
JP5669111B2 (ja) * | 2010-11-10 | 2015-02-12 | 国立大学法人東京工業大学 | アラレマイシン又はその誘導体を有効成分とする抗マラリア薬 |
US9314443B2 (en) | 2011-10-12 | 2016-04-19 | National Center For Child Health And Development | Enhancer of survival of transplanted organ |
WO2021054473A1 (ja) * | 2019-09-19 | 2021-03-25 | 国立大学法人 東京大学 | 鎌状赤血球症の改善及び/又は予防剤 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2722041B1 (en) * | 2011-06-16 | 2018-10-24 | SBI Pharmaceuticals Co., Ltd. | Therapeutic agent for allergic rhinitis |
EP3168296B1 (en) * | 2014-07-11 | 2020-09-09 | SBI Pharmaceuticals Co., Ltd. | Agent for improving normal development rate of fertilized eggs |
US10925963B2 (en) * | 2015-06-22 | 2021-02-23 | Washington University | Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor |
CL2016003379A1 (es) * | 2016-12-29 | 2017-08-04 | Univ Santiago Chile | “composición que comprende ácido delta-aminolevulínico (ala) o un derivado del mismo y oxianiones y teluro o sus derivados y su uso para el control de patógenos.” |
CN109495427B (zh) * | 2017-09-12 | 2021-05-07 | 腾讯科技(深圳)有限公司 | 多媒体数据展示方法、装置、存储介质和计算机设备 |
CN108635581A (zh) * | 2018-05-23 | 2018-10-12 | 昆药集团股份有限公司 | 一种组合物及其在制备***的药物中的应用 |
CN113952360B (zh) * | 2021-09-14 | 2023-03-10 | 上海交通大学 | 一种亚铁离子在治疗疟疾的药物中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2731032B2 (ja) | 1989-07-28 | 1998-03-25 | クイーンズ ユニバーシティ アット キングストン | 光化学療法による悪性および非悪性病変の検出および治療方法 |
JP2002512205A (ja) | 1998-04-22 | 2002-04-23 | マルティ アレクサンドル | 組織病変部の診断または治療のための溶液 |
JP2006124372A (ja) | 2004-09-29 | 2006-05-18 | Cosmo Oil Co Ltd | 腫瘍診断剤 |
JP3810018B2 (ja) | 2004-04-28 | 2006-08-16 | 嘉恭 伊藤 | 育毛剤 |
JP3991063B2 (ja) | 2005-04-28 | 2007-10-17 | 嘉恭 伊藤 | 皮膚外用剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955490A (en) * | 1989-07-28 | 1999-09-21 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
US6710066B2 (en) * | 1989-07-28 | 2004-03-23 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
WO2006096492A2 (en) * | 2005-03-04 | 2006-09-14 | Dusa Pharmaceuticals, Inc. | Compositions and methods for reducing photosensitivity associated with photodynamic therapy |
-
2011
- 2011-05-18 KR KR1020127029697A patent/KR20120137506A/ko active Application Filing
- 2011-05-18 NZ NZ603465A patent/NZ603465A/xx unknown
- 2011-05-18 JP JP2012515757A patent/JP5582441B2/ja active Active
- 2011-05-18 KR KR1020147026883A patent/KR101723834B1/ko active IP Right Grant
- 2011-05-18 US US13/698,090 patent/US9089530B2/en active Active
- 2011-05-18 WO PCT/JP2011/002770 patent/WO2011145343A1/ja active Application Filing
- 2011-05-18 EP EP11783280.8A patent/EP2572711B1/en active Active
- 2011-05-18 CN CN2011800242058A patent/CN102905702A/zh active Pending
- 2011-05-18 AU AU2011256661A patent/AU2011256661B2/en active Active
- 2011-05-18 BR BR112012029170A patent/BR112012029170B1/pt active IP Right Grant
- 2011-05-18 CN CN201610470997.6A patent/CN106109455A/zh active Pending
- 2011-05-18 CA CA2799491A patent/CA2799491C/en active Active
-
2015
- 2015-06-22 US US14/745,823 patent/US9463175B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2731032B2 (ja) | 1989-07-28 | 1998-03-25 | クイーンズ ユニバーシティ アット キングストン | 光化学療法による悪性および非悪性病変の検出および治療方法 |
JP2002512205A (ja) | 1998-04-22 | 2002-04-23 | マルティ アレクサンドル | 組織病変部の診断または治療のための溶液 |
JP3810018B2 (ja) | 2004-04-28 | 2006-08-16 | 嘉恭 伊藤 | 育毛剤 |
JP2006124372A (ja) | 2004-09-29 | 2006-05-18 | Cosmo Oil Co Ltd | 腫瘍診断剤 |
JP3991063B2 (ja) | 2005-04-28 | 2007-10-17 | 嘉恭 伊藤 | 皮膚外用剤 |
Non-Patent Citations (6)
Title |
---|
ARCH. BIOCHEM. BIOPHYS., vol. 316, no. 1, 1995, pages 607 - 611, XP055106497 * |
BIOCHEM. PHARMACOL., vol. 58, 1999, pages 375 - 382, XP027209677 * |
JID (J. INVESTIGATIVE DERMATOLOGY, vol. 190, 2004, pages 184 - 191 |
See also references of EP2572711A4 |
SHIMING ZHANG ET AL.: "Heme Mediates Cytotoxity from Artemisinin and Serves as a General Anti- Proliferation Target", PLOS ONE, vol. 4, no. 10, 2009, XP055081754, Retrieved from the Internet <URL:http://www.plosone.org/ article/fetchObjectAttachment.action?uri= info%3Adoio2F10.1371%2Fjournal.pone.0007472& representation=PDF> [retrieved on 20110810] * |
VITAMIN, vol. 82, no. 9, 2008, pages 507 - 512, XP008168355 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5669111B2 (ja) * | 2010-11-10 | 2015-02-12 | 国立大学法人東京工業大学 | アラレマイシン又はその誘導体を有効成分とする抗マラリア薬 |
US9314443B2 (en) | 2011-10-12 | 2016-04-19 | National Center For Child Health And Development | Enhancer of survival of transplanted organ |
US9901558B2 (en) | 2011-10-12 | 2018-02-27 | National Center For Child Health And Development | Enhancer of survival of transplanted organ |
US9937138B2 (en) | 2011-10-12 | 2018-04-10 | National Center For Child Health And Development | Enhancer of survival of transplanted organ |
WO2014010206A1 (ja) * | 2012-07-13 | 2014-01-16 | Sbiファーマ株式会社 | 免疫寛容誘導剤 |
JP5904518B2 (ja) * | 2012-07-13 | 2016-04-13 | Sbiファーマ株式会社 | 免疫寛容誘導剤 |
US9399029B2 (en) | 2012-07-13 | 2016-07-26 | Sbi Pharmaceuticals Co., Ltd. | Immune tolerance inducer |
WO2021054473A1 (ja) * | 2019-09-19 | 2021-03-25 | 国立大学法人 東京大学 | 鎌状赤血球症の改善及び/又は予防剤 |
Also Published As
Publication number | Publication date |
---|---|
CN102905702A (zh) | 2013-01-30 |
US9463175B2 (en) | 2016-10-11 |
EP2572711A1 (en) | 2013-03-27 |
CA2799491A1 (en) | 2011-11-24 |
BR112012029170B1 (pt) | 2020-05-19 |
NZ603465A (en) | 2013-10-25 |
US20130108710A1 (en) | 2013-05-02 |
AU2011256661A1 (en) | 2012-11-29 |
US20150283102A1 (en) | 2015-10-08 |
KR20120137506A (ko) | 2012-12-21 |
BR112012029170A2 (pt) | 2017-07-18 |
US9089530B2 (en) | 2015-07-28 |
EP2572711A4 (en) | 2013-11-20 |
JP5582441B2 (ja) | 2014-09-03 |
CA2799491C (en) | 2015-03-17 |
EP2572711B1 (en) | 2017-09-20 |
KR20140121490A (ko) | 2014-10-15 |
JPWO2011145343A1 (ja) | 2013-07-22 |
CN106109455A (zh) | 2016-11-16 |
AU2011256661B2 (en) | 2013-07-11 |
KR101723834B1 (ko) | 2017-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5582441B2 (ja) | 5−アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬 | |
JP2001507696A (ja) | グルタチオンの医薬製剤およびその投与方法 | |
EP0287341A1 (en) | Rectally absorbable form of L-dopa | |
ES2755303T3 (es) | Composición medicinal para potenciar la síntesis de protoporfirina IX | |
JP6052736B2 (ja) | 敗血症の予防剤及び/又は治療剤 | |
EP0207011A2 (en) | Use of some alkanoyl L-carnitines for the manufacture of a medicament for therapeutical treatment of idiopathic and induced Parkinsonism | |
US4218471A (en) | Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents | |
TWI590823B (zh) | Cancerous anemia to improve, prevention agent | |
WO2007086395A1 (ja) | 光線力学的療法用キット | |
CN112888419A (zh) | 用于治疗和预防Leber遗传性视神经病变的组合物和方法 | |
US5486535A (en) | Method for treating toxoplasmosis | |
JP2005132766A (ja) | 光動力学的癌治療薬 | |
JP5669111B2 (ja) | アラレマイシン又はその誘導体を有効成分とする抗マラリア薬 | |
JP2007513948A (ja) | 視神経損傷および網膜損傷の処置のためのスーパーオキシドジスムターゼ模倣物 | |
RU2404976C1 (ru) | Средство, снижающее влечение к алкоголизму, фармацевтическая композиция, способ ее получения, лекарственное средство и способ лечения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180024205.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11783280 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2012515757 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20127029697 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2011783280 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011783280 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2799491 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011256661 Country of ref document: AU Date of ref document: 20110518 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13698090 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012029170 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012029170 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121114 |